Bristol-Myers Squibb Stock News

Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take direct aim at drug imports. The post Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports appeared first on Investor's Business Daily.

Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an illegal monopoly on its blockbuster blood cancer drug Pomalyst, keeping cheaper generic versions off the market.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CRC--US FDA Approves Opdivo plus Yervoy as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair.

With some pharmaceutical stocks paying 4% and higher dividends, they may be the perfect total return idea for the rest of 2025.

Hedge funds are rapidly reducing their exposure to global information technology stocks, with the latest selloff marking the fastest decline in six months.

High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on a high yield can be dangerous because if it ends up getting cut, you could lose all or most of the dividend income, and the stock may crash in the process as dividend investors could look elsewhere for a high payout.

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'